secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0001753926-24-001955
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 2.03, 3.03, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chromocell reincorporates as Nevada corporation Channel Therapeutics; shares convert 1:1
--------------------------------------------------------------------------------

- On Nov 18, 2024, Chromocell Therapeutics (Delaware) merged into its Nevada subsidiary, Channel Therapeutics Corp, as the surviving entity.
- Each outstanding share of Chromocell common stock converted into one share of Channel Therapeutics common stock (same symbol CHRO).
- The reincorporation was approved by a majority of stockholders at the Oct 22, 2024 Annual Meeting; board and officers remain unchanged.
- Stockholder rights may be affected by differences between Nevada Revised Statutes and Delaware General Corporation Law.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624001955/0001753926-24-001955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392624001955/g084563_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-001955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer